computer anti-virus info

MultiCell Technologies, Inc. (OTCBB: MCET) has entered into a long-term agreement with Lundbeck Pharmaceuticals Italy S.p.A. for the supply of one of the active components of MCT-125, MultiCell's Phase IIb drug for the treatment of chronic fatigue in patients with multiple sclerosis (MS).

Multiple sclerosis is an autoimmune disease in which immune cells attack and destroy the myelin sheath protecting neurons in the brain and spinal cord. About two million people worldwide are afflicted with MS, and an estimated 10,000 new MS cases are diagnosed yearly in the USA. Over 75% of MS sufferers report chronic fatigue, and 50% to 60% report chronic fatigue as the worst symptom of their disease. Chronic fatigue severely affects an individual's quality of life. In approximately 30% of MS patients, chronic fatigue is the first symptom, and there is no FDA-approved tre...

StrikeForce Technologies (OTCBB: SKFT) announced the world's first free download of GuardedID® (www.guardedid.com). GuardedID's revolutionary instant encryption technology process with CryptoColor, secures a PC user's typed keystrokes in a visible color of their choice. CryptoColor is a visual verification technology that helps solve the huge global problem of identity theft.

GuardedID's new patent pending keystroke encryption process encrypts all online keystrokes instantly as a user types. GuardedID then delivers those encrypted keystrokes via its own protected pathway, securing such things as usernames, passwords, social security numbers, credit card info, personal & banking information, email, online application personal information, or any other private / corporate information you type when online.

"When ...

Reflex Security (www.reflexsecurity.com) pioneer and innovator in intrusion prevention systems (IPS), today announced that it has joined the SecureIT Alliance formed by Microsoft Corporation (NASDAQ: MSFT). The SecureIT Alliance unites and expands security partnerships to enhance future product interoperability and refine best practices for product deployments.

Customers and partners of both Reflex Security and Microsoft will benefit by having access to the SecureIT community website (www.secureitalliance.org), which features up-to-date information on security solutions, and provides a forum for interactive dialogue. The SecureIT Alliance website also offers current and new customers a searchable membership product & solutions area where IT professionals can access se...

Targeted Genetics Corporation (NASDAQ: TGEN) today announced the issuance of an additional patent related to its adeno-associated virus (AAV) vector technology that describes delivery of genes or delivery of small therapeutic genetic constructs or small therapeutic genetic constructs including therapeutic RNA molecules such as RNAi. U.S. patent #7,125,717 entitled "Metabolically Activated Recombinant Viral Vectors and Methods for Their Preparation and Use" describes the use of AAV vectors that are more efficient for expression of therapeutic genetic constructs.

Single stranded Deoxyribonucleic acid (DNA) vectors like AAV require conversion to a double-stranded DNA form in order for the therapeutic gene of interest to be expressed. The AAV virus DNA is about 4.7 Kb in size. However, a significant number of either genes used in gene therapy as well as genetic co...

Leading SSL VPN provider Aventail today announced that its new SSL VPN platform ST2 has been awarded with IT Week magazine's coveted 2006 Editor's Choice award, receiving five stars out of five. ST2 was lauded for its market-leadership, high-level of security and comprehensive access functionality and praised for the inclusion of extensive Network Access Control (NAC) functionality.

"Aventail's ST2 technology guarantees that the computer systems that are accessing the organization's applications must first meet its security policies, such as being virus-free, or having an up-to-date OS patch," stated Ken Durham, Editor IT Week.

The IT Week review highlights Aventail's new NAC functionality, specifically discussing Aventail's ability to check on the availability of anti-virus, anti-spyware, operating system, and installed service packs on remote PCs trying to access corporate resources. The review also notes the benefits of several innovative new features: Device Watermarking te...

Key figures

Nine months to September 30

Third quarter

Excluding charges related to Chiron acquisition, Q3 Group operating income rises 24% and net income up 22%

(1) Tekturna replaces Rasilez as the proposed global brand name for aliskiren

All product names appearing in italics are trademarks of Novartis Group Companies

Basel, October 19, 2006 -- Commenting on the results, Dr. Daniel Vasella, Chairman and CEO of Novartis, said, "I am pleased that all of our divisions delivered strong results in the first nine months of the year. Pharmaceuticals delivered double-digit growth in our Cardiovascular, Oncology and Neuroscience franchises further strengthening their market positions. Our Vaccines and Diagnostics business is progressing well, already having made the industry's first shipments of injectable influenza vaccines to the US. Thanks to our commitment to innovation, we have a full pipeline and have completed major submissions in the US and ...

Targeted Genetics Corporation (NASDAQ: TGEN) today announced the issuance of a new patent that describes a novel approach for improving the efficiency with which adeno-associated viral (AAV) vectors deliver genes to target cells. This approach covers small molecule compounds and methods that enhance the trafficking of AAV vectors to the nucleus of a host cell. Transport to the nucleus is necessary for expression of delivered genes. The patent, U.S. #7,122,335, is issued to the University of Iowa Research Foundation and is exclusively licensed to Targeted Genetics.

"As a company focused on developing AAV-based products for important therapeutic indications, we strive to enhance the natural properties of AAV that give these vectors great potential in treating a diverse array of diseases," said H. Stewart Parker, president and chief executive officer of Targeted ...

Lipid Sciences, Inc. (NASDAQ: LIPD) announced that a paper entitled "Delipidation of a Hepadnavirus: Viral Inactivation and Vaccine Development" by B.E. Cham*, K. Vickery et.al., appearing in the Journal of Virological Methods 137 (2006) 160-163, outlined a novel approach to the development of a vaccine against viral infection utilizing the process of viral delipidation. In this study, delipidated Hepatitis B virus was successfully used to vaccinate and protect young ducklings against a lethal challenge. The duck/duck hepatitis B model was chosen to demonstrate this principle because it has been used as a surrogate for Hepatitis B. The second aim of the study was to determine whether removing lipids from the envelope of DHBV (Duck Hepatitis B Virus) would preserve the viral proteins in their antigenic form -- which was successfully demonstrated. The results of thi...

Lipid Sciences, Inc. (NASDAQ: LIPD) announced that a paper entitled "Delipidation of a Hepadnaviurs: Viral Inactivation and Vaccine Development" by B.E. Cham*, K. Vickery et.al., appearing in the Journal of Virological Methods 137 (2006) 160-163, outlined a novel approach to viral inactivation by the process of delipidation. In this study, delipidated Hepatitis B virus was successfully used to vaccinate and protect young ducklings against a lethal challenge. The duck/duck hepatitis B model was chosen to demonstrate this principal because it has been used as a surrogate for Hepatitis B. The second aim of the study was to determine whether removing lipids from the envelope of DHBV (Duck Hepatitis B Virus) would preserve the viral proteins in their antigenic form -- which was successfully demonstrated. The results of this study support the premise that delipidati...

Lipid Sciences, Inc. (NASDAQ: LIPD) announced that the Company's HDL Selective Delipidation technology platform was represented at presentations and workshops conducted at the New York ACE Meeting, a prestigious cardiovascular care conference held October 8-11. Presentations were made by: Dr. H. Bryan Brewer, Jr., Lipid Sciences' Vice Chairman, Chief Scientific Director, and member of the Lipid Sciences Board of Directors; and Dr. Ron Waksman, Director, Experimental Angioplasty and New Technologies, Cardiovascular Institute, and Associate Director, Division of Cardiology, Washington Hospital Center, and Principal Investigator for Lipid Sciences' "first in man" clinical trial for HDL Selective Delipidation.

New York ACE is a unique combination of live demonstration cases, lectures, focused workshops, case review sessions, and simulator training offered by a r...